Literature DB >> 10347112

Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines.

H Yano1, A Iemura, M Haramaki, S Ogasawara, A Takayama, J Akiba, M Kojiro.   

Abstract

Type I interferon (IFN) receptor consists of two chains (Hu-IFN-alphaR1 and Hu-IFN-alphaR2), and Hu-IFN-alphaR2 takes a soluble (Hu-IFN-alphaR2a), short (Hu-IFN-alphaR2b), or long (Hu-IFN-alphaR2c) form. We examined the expression of type I IFN receptor, the growth-suppression effect of IFN-alpha, and their relationship in 13 liver cancer cell lines. With reverse-transcription polymerase chain reaction (RT-PCR) analysis, the expressions of Hu-IFN-alphaR1, Hu-IFN-alphaR2a, and Hu-IFN-alphaR2c were confirmed in all cell lines, and that of Hu-IFN-alphaR2b in 12 cell lines. All cell lines expressed mRNAs of a transcriptional activator, interferon regulatory factor (IRF)-1, and its antagonistic repressor (IRF-2). Flow cytometry revealed weak expression of Hu-IFN-alphaR2 on the cell surface in 12 cell lines. The soluble-form protein of Hu-IFN-alphaR2 was detected at varying levels in culture supernatants of all cell lines with enzyme-linked immunosorbent assay (ELISA). Cell proliferation was suppressed in proportion to the dose of human natural IFN-alpha at 96 hours of culture, but it was not clearly related to the expression of Hu-IFN-alphaR2 protein on the cell surface. Investigations on the morphology, DNA, and cell cycle presented four growth suppression patterns as a result of IFN-alpha: 1) induction of apoptosis and blockage of cell cycle at the S phase (9 cell lines); 2) blockage at the S phase (2 cell lines); 3) induction of apoptosis and blockage at the G2/M phase (1 cell line); and 4) blockage at the G1 phase (1 cell line). There was no evidence showing that changes in the expressions of Bcl-2, Bcl-xL, Bak, and Bax lead directly to IFN-alpha-mediated apoptosis. Our findings demonstrated that IFN-alpha would express growth-suppression effects at varying degrees by inducing inhibition of cell-cycle progression with or without apoptosis, regardless of the expression level of Hu-IFN-alphaR2 protein on the cell surface.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10347112     DOI: 10.1002/hep.510290624

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  31 in total

Review 1.  Current Status of Hepatic Arterial Infusion Chemotherapy.

Authors:  Shuntaro Obi; Shinpei Sato; Toshihiro Kawai
Journal:  Liver Cancer       Date:  2015-08-12       Impact factor: 11.740

2.  Tumour lineage-homing cell-penetrating peptides as anticancer molecular delivery systems.

Authors:  Eisaku Kondo; Ken Saito; Yuichi Tashiro; Kaeko Kamide; Shusei Uno; Tomoko Furuya; Masao Mashita; Kiichiro Nakajima; Tomoyuki Tsumuraya; Naoya Kobayashi; Masahiro Nishibori; Mitsune Tanimoto; Masayuki Matsushita
Journal:  Nat Commun       Date:  2012-07-17       Impact factor: 14.919

3.  Differential effects of interferon alpha-2b and beta on the signaling pathways in human liver cancer cells.

Authors:  Kazuya Matsumoto; Jun-ichi Okano; Yoshikazu Murawaki
Journal:  J Gastroenterol       Date:  2005-07       Impact factor: 7.527

4.  Toxicity and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma (Review).

Authors:  Hiroki Ueda; Hiroko Fukuchi; Chigusa Tanaka
Journal:  Oncol Lett       Date:  2011-11-02       Impact factor: 2.967

5.  Long-term interferon therapy after radiofrequency ablation is effective in treating patients with HCV-associated hepatocellular carcinoma.

Authors:  Soji Shimomura; Naoto Ikeda; Masaki Saito; Akio Ishii; Tomoyuki Takashima; Yoshiyuki Sakai; Shohei Yoshikawa; Nobuhiro Aizawa; Hironori Tanaka; Yoshinori Iwata; Hirayuki Enomoto; Hiroyasu Imanishi; Teruhisa Yamamoto; Hisato Jomura; Hideji Nakamura; Hiroko Iijima; Shuhei Nishiguchi
Journal:  Hepatol Int       Date:  2010-09-24       Impact factor: 6.047

6.  Antiproliferative effect of ME3738, a derivative of soyasapogenol, on hepatocellular carcinoma cell lines in vitro and in vivo.

Authors:  Sachiko Ogasawara; Jun Akiba; Masamichi Nakayama; Hironori Kusano; Hirohisa Yano
Journal:  Biomed Rep       Date:  2016-10-25

7.  Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma.

Authors:  Kazuhiro Kasai; Akira Ushio; Yukiho Kasai; Kei Sawara; Yasuhiro Miyamoto; Kanta Oikawa; Hidekatsu Kuroda; Yasuhiro Takikawa; Kazuyuki Suzuki
Journal:  Int J Clin Oncol       Date:  2010-12-04       Impact factor: 3.402

8.  Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus.

Authors:  Jian Wu; Wen-Jin Huang; Huan-Yu Wang; Ya-Feng Wang; Bao-Gang Peng; Qi Zhou
Journal:  Med Oncol       Date:  2015-02-18       Impact factor: 3.064

9.  Systemic combined chemotherapy with low dose of 5-fluorouracil, cisplatin, and interferon-alpha for advanced hepatocellular carcinoma: a pilot study.

Authors:  Yasuji Komorizono; Kazunori Kohara; Makoto Oketani; Masahiko Maeda; Toshihiko Shibathou; Shuhou Shigenobu; Yasusi Hiramine; Naruhiro Yamasaki; Takushi Arima; Ishibashi Kazuaki; Terukatsu Arima
Journal:  Dig Dis Sci       Date:  2003-05       Impact factor: 3.199

10.  Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells.

Authors:  Hiroshi Wada; Hiroaki Nagano; Hirofumi Yamamoto; Takehiro Noda; Masahiro Murakami; Shogo Kobayashi; Shigeru Marubashi; Hidetoshi Eguchi; Yutaka Takeda; Masahiro Tanemura; Koji Umeshita; Yuichiro Doki; Masaki Mori
Journal:  BMC Cancer       Date:  2009-10-12       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.